在加拿大重症监护病房中分离的革兰氏阴性杆菌的体外活性研究：新型铁载体头孢菌素头孢地尔。
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
机构信息
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 727 McDermot Avenue, Winnipeg, Manitoba, R3E 3P5, Canada.
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 727 McDermot Avenue, Winnipeg, Manitoba, R3E 3P5, Canada; Department of Clinical Microbiology, Shared Health Manitoba. MS673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada.
出版信息
Diagn Microbiol Infect Dis. 2020 May;97(1):115012. doi: 10.1016/j.diagmicrobio.2020.115012. Epub 2020 Feb 4.
The in vitro activity of cefiderocol was evaluated against Gram-negative bacilli isolated from patients in Canadian intensive care units from 2015 to 2017 using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method and interpretive criteria. All 800 isolates of Gram-negative bacilli tested were susceptible to cefiderocol (MIC ≤4 μg/ml), including isolates of ESBL-producing (n=40), AmpC-producing (n=6), and carbapenem-nonsusceptible (n=21) Enterobacterales, carbapenem-nonsusceptible (n=54) and multidrug-resistant (n=29) Pseudomonas aeruginosa, Stenotrophomonas maltophilia (n=66), and Acinetobacter baumannii (n=11).
采用临床和实验室标准协会（CLSI）肉汤微量稀释法和解释标准，评估了头孢地尔在 2015 年至 2017 年期间从加拿大重症监护病房患者中分离出的革兰氏阴性菌的体外活性。测试的 800 株革兰氏阴性菌对头孢地尔均敏感（MIC≤4μg/ml），包括产 ESBL（n=40）、产 AmpC（n=6）和耐碳青霉烯类肠杆菌科（n=21）、耐碳青霉烯类（n=54）和多重耐药（n=29）铜绿假单胞菌、嗜麦芽寡养单胞菌（n=66）和鲍曼不动杆菌（n=11）的分离株。
Zotero 插件